Solid Biosciences (SLDB) filed a registration statement Thursday for the potential sale of up to $400 million of its securities from time to time.

The offering covers the company's debt securities, common stock, preferred stock, depositary shares, warrants, and units.

The biotech company said it plans to use the proceeds for general corporate purposes, unless otherwise specified at the time of the offerings.